The 78% QoQ increase in ordering institutions and 31% vial order growth suggest the LYMPHIR launch is gaining tangible traction. Monitor the next quarterly filing (10-K for period ending September 30, 2026) for actual revenue recognition from wholesale orders. The trajectory toward 100 priority institutions by year-end is a key milestone to watch.
Price Chart
Executive Summary
Citius Pharma's subsidiary Citius Oncology reported strong commercial momentum for its newly launched cancer drug LYMPHIR, with a 78% QoQ increase in new institutional accounts and a 31% increase in vial orders. The product is now available at 42 institutions with near-universal payer coverage, and management targets 100 priority institutions by year-end. The filing provides real traction metrics for the recently launched product but does not disclose specific revenue figures.
Key Facts
- New institutional accounts ordering LYMPHIR increased 78% quarter-over-quarter (Q2 2026 vs Q1 2026)
- LYMPHIR is now available in 42 institutions including academic oncology centers and NCCN institutions
- Vials ordered by institutions from wholesalers rose 31% during the quarter ended June 30, 2026
- Company tracking indicates LYMPHIR has secured near-universal payer coverage
- Initial CTCL market for LYMPHIR currently exceeds $400 million per management estimate
- Citius Oncology anticipates more than 20 additional institutions in the current quarter, targeting 100 priority institutions by year-end
Financial Impact
No specific revenue figures disclosed; operational metrics show accelerating institutional adoption and vial demand
Risk Factors
- LYMPHIR has a boxed warning for capillary leak syndrome, which may limit physician adoption
- No actual revenue figures disclosed — wholesale ordering does not guarantee revenue recognition
- Heavy reliance on commercial execution with a small internal launch team; expanded teams may take time to show impact
- Citius Pharma has a $17M market cap and may need additional financing to support commercial operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-085432 |
| Document: ea0300373-8k_citius.htm | 0001213900-26-085432 |
| Document: 0001213900-26-085432-index-headers.html | 0001213900-26-085432 |
| Document: 0001213900-26-085432-index.html | 0001213900-26-085432 |
| Document: 0001213900-26-085432.txt | 0001213900-26-085432 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.4582 | awaiting T+60 | — | $0.4030 (−12.05%) |
Aug 5, 2026 11w ago | 8-K | $0.7809 | awaiting T+60 | — | $0.4030 (−48.39%) |
Jun 3, 2026 20w ago | EFFECT | $0.5800 $0.6290 | ▼ −8.45% | ▼ −5.95% | $0.4030 (+30.52%) |
Jun 1, 2026 21w ago | 8-K | $0.6030 $0.5771 | ▼ −4.30% | ▼ −5.41% | $0.4030 (−33.17%) |
May 22, 2026 22w ago | S-3 | $0.6970 $0.6375 | ▲ +8.54% | ▲ +11.26% | $0.4030 (+42.18%) |
May 15, 2026 23w ago | 8-K | $0.5270 $0.7650 | ▼ −45.16% | ▼ −40.31% | $0.4030 (+23.53%) |
Apr 24, 2026 26w ago | 8-K | $0.6910 $0.5623 | ▲ +18.63% | ▲ +23.40% | $0.4030 (+41.68%) |
Apr 24, 2026 26w ago | 424B5 | $0.7700 $0.5455 | ▲ +29.16% | ▲ +34.24% | $0.4030 (+47.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers